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Abstract: 
     Antihyperglycemic interventions have centered on increasing insulin availability, 
improving  insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in 
patients with type 2 diabetes mellitus. An alternative strategy is to enhance urinary glucose 
excretion by targeting renal sodium-glucose co-transporters (SGLTs). Sodium-glucose co-
transporter 2 (SGLT2) inhibitors reduce blood glucose by increasing urinary glucose 
excretion and present a valuable therapeutic option for the treatment of type 2 diabetes. 
Presently, clinically available SGLT2 inhibitors include canagliflozin, dapagliflozin 
and empagliflozin [1, 2]. 
43 
Keywords: sodium-glucose co-transporter 2 inhibitors, glucose, type 2 diabetes, 
cardiovascular effects  
 
1. Sodium-glucose co-transporter 2 inhibitors - mechanism of action 
     Glucose, which is a polar compound, cannot penetrate through the walls of the nephron 
which are made of lipids. Consequently, glucose is reabsorbed by the nephrons with help 
of glucose transporters which utilize ATP and generate an ionic gradient that helps in 
the transport of glucose. Described glucose transporters are present in the proximal 
convoluted tubule (PCT) of the nephron. The apical membrane of the PCT contains of two 
types of Na
+
/K
+
 co-transporters: SGLT1 and SGLT2. SGLT2 reabsorb of approximately 90% 
of the filtered glucose load whereas SGLT1 is responsible for the remaining 10% (Figure 1).  
Therefore, SGLT2 are an ideal target for the treatment of diabetes. 
 
Figure 1 – Mechanism of action of SGLT2 inhibitors 
 
     The active transport of glucose is carried out by SGLT through the Na
+
/K
+
ATPase channel 
(present in the basolateral membrane of the PCT): the Na
+
/K
+
 ATPase pump expels out 
3 Na
+
 ions from the lumen into the blood and in return brings in 2 K
+
 ions. This leads 
to formation of a downhill Na
+
 ion gradient.  The SGLT proteins employ the energy generated 
by this downhill gradient to transport 1 glucose molecule and 1 Na
+
 ion across the apical 
membrane of the PCT.  The glucose is then extruded into the blood with the help of facilitated 
transport by glucose transporter type 2 (GLUT2) and glucose transporter type 1 (GLUT1), 
which are present on the basolateral membrane of the PCT.  
     SGLT2 lower blood glucose and glycated hemoglobin (A1C) levels but this effect is 
limited due to the filtered load of glucose and the osmotic diuresis. The glucose-lowering 
effect is independent of insulin – that is why SGLT2 inhibitors usually do not cause  
hypoglycaemia [3, 4, 5]. 
 
2. Indications  
      The majority of patients with type 2 diabetes does not demand SGLT2 inhibitors as initial 
therapy. Most patients should be firstly treated with diet, weight reduction, exercise 
and metformin. However, SGLT2 inhibitors might be useful option in: 
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 obese and hypertensive patients (because of potential weight loss and antihypertensive 
benefits) 
 patients with overt cardiovascular disease (eg heart failure) not reaching glycemic 
goals with metformin and lifestyle modifications 
 patients with nephropathy (urine albumin-to-creatinine >300 mg/g and estimated 
glomerular filtration rate (eGFR) <90 mL/min/1.73m
2
) 
 as a second agent in patients with inadequate control on metformin who are unable 
to consider injection therapy  
 patients who are at high risk of hypoglycemia (the risk of hypoglycemia with SGLT2 
inhibitors is small when compared to insulin and sulfonylureas)  
 as a third-line agent in patients with inadequate glycemic control on two oral agents 
(eg, metformin and sulfonylurea) if for some reason combination metformin 
and  insulin is not a therapeutic option 
 as a third-line agent in patients not adequately controlled on metformin and insulin 
therapy, in whom glucagon-like peptide-1 (GLP-1) receptor agonists are 
contraindicated and increasing insulin dosing would lead to weight gain 
 treatment of diabetic nephropathy - SGLT2 inhibitors reduce the risk of kidney disease 
progression and cardiovascular disease in patients with type 2 diabetes 
with nephropathy (estimated or measured urine albumin excretion >300 mg per day) 
and an estimated GFR (eGFR) ≥30 mL/min per 1.73 m2 [6, 7]. 
 
3. Contraindications  
       Patients with predisposition for bacterial urinary tract infections or genitourinary yeast 
infections should be warned of increased risk while using SGLT2 inhibitors. These agents are 
also contraindicated for patients with: 
 type 1 diabetes 
 type 2 diabetes and renal insufficiency (GFR < 45 mL/min/1.73m2) 
 ketosis-prone type 2 diabetes [8]. 
 
4. Drug interaction 
       SGLT2 inhibitors may cause a mild degree of dehydration. Therefore, they should not be 
used with other drugs predisposing to acute renal injury (nonsteroidal anti-inflammatory 
drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, 
contrast agents, mannitol, calcineurin inhibitors). For this reason, it seems reasonable 
to discontinue SGLT2 inhibitors before performing any diagnostic imaging with  contrast 
agents.  
       What is more, SGLT2 inhibitors should be used with caution if the patient has 
comorbidities that might predispose to acute renal injury (hypovolemia, heart failure, liver 
injury, renal artery stenosis). As a consequence, patients should be clinically evaluated before 
starting SGLT2 inhibitors therapy - volume status, renal function (serum creatinine with 
eGFR) and liver function should be assessed [9].  
 
5. Clinical outcomes  
        SGLT2 inhibitors have a unique mechanism of action. Not only, do they bring out 
the hypoglycemic effect and weight reduction, but also reduce blood pressure thanks to 
diuretic and natriuretic effect. The benefits from using SGLT2 inhibitors are following: 
 glycemic efficacy — SGLT2 inhibitors are relatively weak glucose-lowering agents, with 
mean reductions in A1C compared with placebo ranging between 0,4 to 1,1 percentage 
depending on baseline level of hyperglycemia;  
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 cardiovascular effects — empagliflozin and canagliflozin appear to decrease mortality 
in patients with type 2 diabetes and overt cardiovascular disease (CVD); 
dapagliflozin does not appear to reduce atherosclerotic cardiovascular morbidity 
or cardiovascular mortality, but similar to empagliflozin and canagliflozin, dapagliflozin 
reduces hospitalization for heart failure 
 microvascular outcomes — there are a number of trials evaluating microvascular 
outcomes in patients taking SGLT2 inhibitors: in a meta-analysis of the 3 major CVD 
outcome trials, empagliflozin, canagliflozin and dapagliflozin reduced progression 
of nephropathy, with a similar effect observed in patients with established atherosclerotic 
CVD or multiple risk factors for CVD  
 weight loss — SGLT2 inhibitors decrease weight: in 12-week trials 
of dapagliflozin, canagliflozin, and empagliflozin, weight loss of 2 to 3 kg was reported 
and the weight loss appears to be sustained over time; however, due to the osmotic 
and possibly diuretic effect of flozins it is important to differentiate between a weight 
reduction because of fluid loss and that due to fat loss [10, 11, 12, 13, 14, 15, 16]. 
 
6. Adverse effects of SGLT2 inhibitors 
      The most common side effects caused by SGLT2 inhibitors include fungal infections 
of  the external genitourinary organs and urinary tract infections. In addition, especially 
among the elderly patients with impaired renal function, who take diuretics, SGLT2 inhibitors 
may cause symptomatic hypotension. 
Adverse effects of SGLT2 inhibitors are following: 
 infections of genitourinary tract – increased incidence of vulvovaginal candidiasis, 
urinary tract infections and potentially fatal urosepsis, pyelonephritis and necrotizing 
fasciitis of the perineum (Fournier's gangrene), related to the induction of glucosuria 
(which supports the growth of fungi or other organisms and promotes more frequent 
genitourinary infections) 
 bladder cancer – especially among dapagliflozin users (it can be associated with 
increased surveillance of patients treated for genitourinary infections) 
 hypotension — SGLT2 inhibitors cause an osmotic diuresis and intravascular volume 
contraction; therefore in older patients taking diuretics, angiotensin-converting enzyme 
(ACE) inhibitors, or angiotensin receptor blockers (ARBs), SGLT2 inhibitors may cause 
symptomatic hypotension  
 acute kidney injury – in patients taking canagliflozin or dapagliflozin, but probably other 
risk factors occurred (eg, depleted volume, hypotension, or taking other medications that 
could affect the kidneys) 
 bone fractures — a possible mechanism, particularly for fractures occurring in older 
individuals after only 12 weeks of therapy, is orthostatic hypotension resulting in postural 
dizziness and falls, but also SGLT2 inhibitors may adversely affect bone density 
 diabetic ketoacidosis — that is why serum ketones should be obtained in any patient with 
nausea, vomiting, or malaise while taking SGLT2 inhibitors, and SGLT2 inhibitors should 
be discontinued if acidosis is confirmed 
 amputations — compared with some oral and injectable diabetes agents, SGLT2 
inhibitors are associated with an increased risk of amputation; as a consequence, patients 
taking SGLT2 inhibitors should be monitored for signs and symptoms of foot ulceration 
(so called diabetic foot) [17, 18, 19, 20]. 
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7. Drug information  
      Empagliflozin, canagliflozin and dapagliflozin are representatives of SGLT2 inhibitors 
used in clinical practice. Soon, ertugliflozin will be also available. 
a) Empagliflozin  
 dosing: the initial dose is 10 mg daily, and it can be increased to 25 mg once daily (as 
tolerated to achieve glycemic goals), empagliflozin is taken orally once daily in 
the morning with or without food  
 should not be initiated in patients with eGFR <45 mL/min/1.73 m2 
 may be used in patients with hepatic impairment. 
 indications: treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to 
improve glycemic control; risk reduction of cardiovascular mortality in adults with 
type 2 diabetes mellitus and established cardiovascular disease 
 contraindications: history of serious hypersensitivity to empagliflozin or any 
component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 
m
2
), end-stage renal disease or dialysis 
 adverse reactions: genitourinary fungal infection, urinary tract infections, increased 
urine output, dyslipidemia, increased thirst, nausea, increased haematocrit, 
hypotension (due to intravascular volume depletion), bone fractures; risk 
of intravascular volume depletion, renal impairment may be increased in elderly 
patients 
 monitoring parameters: blood glucose, HbA1c,renal function, volume status (eg, blood 
pressure, hematocrit, electrolytes); LDL-C; if signs/symptoms of ketoacidosis 
(eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis 
by direct measurement of blood ketones and arterial pH [21] 
b) Canagliflozin 
 dosing: the initial dose is 100 mg once daily, and it can be increased to 300 mg daily 
to achieve glycemic goals, canagliflozin is taken orally before the first meal of the day 
 eGFR ≥30 to <45 mL/minute/1.73 m2: Use not recommended for initiation of therapy 
or when eGFR is persistently <45 mL/minute/1.73 m
2
. 
 indications: treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as 
an adjunct to diet and exercise to improve glycemic control; risk reduction of major 
cardiovascular events (cardiovascular death, nonfatal MI, and nonfatal stroke) in 
adults with type 2 diabetes mellitus and established cardiovascular disease 
 contraindications: history of serious hypersensitivity to canagliflozin or any 
component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 
m
2
); end-stage renal disease or patients on dialysis 
 adverse reactions: increased serum potassium, genitourinary fungal infection, urinary 
tract infection, increased urine output, renal insufficiency, falling, fatigue, 
hypoglycemia, hypovolemia, increased thirst, abdominal pain, constipation, nausea, 
increased haemoglobin, hypersensitivity reactions, bone fractures, hypotension, 
ketoacidosis, lipid abnormalities, lower limb amputation  
 monitoring parameters: blood glucose, HbA1c, renal function, volume status (eg, blood 
pressure, hematocrit, electrolytes); serum potassium, serum magnesium and 
phosphate, LDL-C, hypersensitivity reactions, lower limb and feet (sores, ulcers, 
infection); if signs/symptoms of ketoacidosis (eg, nausea/vomiting, abdominal pain, 
malaise, shortness of breath), confirm diagnosis by direct measurement of blood 
ketones and arterial pH [22] 
c) Dapagliflozin 
 dosing: 10 mg once daily can be taken any time of day with or without food 
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 if eGFR ≥45 mL/minute/1.73 m2: no dosage adjustment necessary, but if eGFR 30 to 
<45 mL/minute/1.73 m
2
: the use is not recommend, however, recommendations 
regarding indicated level of eGFR for initiation or continued use may vary in other 
regions 
 indications: as an adjunct to diet and exercise to improve glycemic control in adults 
with type 2 diabetes mellitus 
 contraindications: history of serious hypersensitivity to dapagliflozin or any 
component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 
m
2
), end-stage renal disease (ESRD), or patients on dialysis 
 adverse reactions: urinary tract infections, genitourinary fungal infection, increased 
urine output, influenza dyslipidemia, nausea, hyperphosphatemia, nasopharyngitis, 
hypovolemia, renal insufficiency, back pain, limb pain, bone fractures, hypotension, 
ketoacidosis, lipid abnormalities, necrotizing fasciitis, bladder cancer, renal or hepatic 
impairment 
 monitoring parameters: blood glucose, HbA1c, renal function, LDL-C, volume status 
(eg, blood pressure, hematocrit, electrolytes); if signs/symptoms of ketoacidosis 
(eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis 
by direct measurement of blood ketones and arterial pH [23] 
d) Ertugliflozin 
 dosing: the initial dose is 5 mg once daily and may be increased to a maximum dose of 
15 mg once daily to achieve glycemic goals, ertugliflozin is taken once daily in the 
morning with or without food 
 if eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in 
preexisting impairment or continued use when eGFR is persistently within this range 
during therapy 
 indications: as an adjunct to diet and exercise to improve glycemic control in adults 
with type 2 diabetes mellitus 
 contraindications: history of serious hypersensitivity reaction to ertugliflozin or any 
component of the formulation; severe renal impairment, end-stage renal disease, or 
dialysis 
 adverse reactions: genitourinary fungal infection, headache, hypovolemia, 
hypoglycaemia, increased thirst, weight loss, increased urine output, vulvovaginal 
pruritus, back pain, nasopharyngitis, renal insufficiency, hypersensitivity reactions, 
bone fractures, hypotension, ketoacidosis, lipid abnormalities, lower limb amputation 
 monitoring parameters: blood glucose, HbA1c, renal function, volume status (eg, blood 
pressure, hematocrit, electrolytes), phosphate, LDL-C, genital mycotic infections and 
urinary tract infection, hypersensitivity reactions, lower limb and feet (sores, ulcers, 
infection); if signs/symptoms of ketoacidosis confirm diagnosis by direct measurement 
of blood ketones and arterial pH [24]. 
 
8. Choice of therapy 
 
      SGLT2 inhibitors are administered to individuals with type 2 diabetes who had previously 
reported poorly controlled blood glucose. They are effective in: reducing HbA1c, improving 
weight loss in conjunction with advice on lifestyle and diet, lowering systolic blood pressure 
and decreasing FPG levels. When a decision has been made to use an SGLT2 inhibitor, 
empagliflozin, canagliflozin, dapagliflozin,  and ertugliflozin are available options.  
       If a patient with type 2 diabetes has a prior history of myocardial infarction or stroke, 
empagliflozin is suggested rather than another SGLT2 inhibitor. Although canagliflozin also 
shows cardiovascular benefits, there is an increase in the risk of lower limb amputations 
and  fractures in canagliflozin-treated patients that was not observed in trials of empagliflozin 
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or dapagliflozin. There are no trials directly comparing the individual SGLT2 inhibitors, but 
in network meta-analyses canagliflozin 300 mg reduced A1C to a slightly greater extent 
than dapagliflozin 10 mg or empagliflozin 25 mg (mean difference -0.2 percentage points) 
[25, 26]. 
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